Tadalafil: a long-acting PDE5 inhibitor for the management of erectile dysfunction

ISSN： 1475-0708

Source： Therapy, Vol.1, Iss.2, 2004-11, pp. : 185-196

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A 6 month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Latin American men with erectile dysfunction

By Rubio-Aurioles Eusebio

Current Medical Research and Opinion, Vol. 29, Iss. 6, 2013-06 ,pp. : 695-706

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and safety of long‐term tadalafil 5 mg once daily combined with sildenafil 50 mg as needed at the early stage of treatment for patients with erectile dysfunction

ANDROLOGIA (ELECTRONIC), Vol. 47, Iss. 1, 2015-02 ,pp. : 20-24

John Wiley & Sons Inc

Access to resources Recommend Favorite

A 6-month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Middle Eastern and North African men with erectile dysfunction

By El-Meliegy Amr

Current Medical Research and Opinion, Vol. 29, Iss. 6, 2013-06 ,pp. : 707-717

Informa Healthcare

Access to resources Recommend Favorite

Phosphodiesterase type 5 inhibitor therapy: identifying and exploring what attributes matter more to clinicians and patients in the management of erectile dysfunction

By Axilrod Andrew C.

Current Medical Research and Opinion, Vol. 23, Iss. 12, 2007-12 ,pp. : 3189-3198

Informa Healthcare

Access to resources Recommend Favorite

Tadalafil 5 mg Once Daily Improves Lower Urinary Tract Symptoms and Erectile Dysfunction: A Systematic Review and Meta‐analysis

LUTS, Vol. 10, Iss. 1, 2018-01 ,pp. : 84-92

John Wiley & Sons Inc

Access to resources Recommend Favorite